For the Inventor, By the Inventor

Enter assignee name

Ribomic Inc.

USPTO Granted Patents = 13

CIPO Patents = 3

EPO Patents = 7

Trademarks = 1

Forward Citations = 32

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Yoshikazu Nakamura (10 out of 14 patents)

Shin Miyakawa (6 out of 7 patents)

Ling Jin (5 out of 6 patents)

4. Masatoshi Fujiwara (5 out of 32 patents)

5. Takashi Matsui (3 out of 109 patents)

6. Hisanao Hiramatsu (3 out of 3 patents)

7. Sadatoshi Sakuma (3 out of 15 patents)

8. Akio Suzumura (2 out of 9 patents)

9. Satoko Yamazaki (2 out of 2 patents)

10. Masahiro Muraguchi (2 out of 2 patents)

11. Jinyan Wang (2 out of 2 patents)

12. Akira Ishiguro (1 out of 5 patents)

13. Kenji Kadomatsu (1 out of 12 patents)

14. Ping Mu (1 out of 1 patent)

15. Hisako Ikeda (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 11639503 - Anti-chymase aptamer and use for same (2023-05-02),

2. 11473089 - Aptamer for ADAMTS5 and use for aptamer for ADAMTS5 (2022-10-18),

3. 10260070 - Aptamer for NGF and use thereof (2019-04-16),

4. 9987298 - Aptamer for FGF2 and use thereof (2018-06-05),

5. 9567589 - NGF aptamer and application thereof (2017-02-14),

6. 9506070 - Aptamer against midkine and applications thereof (2016-11-29),

7. 9175292 - Aptamer for NGF and use thereof (2015-11-03),

8. 9012420 - Aptamer for chymase, and use thereof (2015-04-21),

9. 8772259 - Aptamer to FGF2 and use thereof (2014-07-08),

10. 8716230 - Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells (2014-05-06),

11. 8637656 - Nucleic acid capable of binding to immunoglobulin G and use thereof (2014-01-28),

12. 8128934 - Method for treatment or prevention of disease associated with functional disorder of regulatory T cell (2012-03-06),

13. 8080649 - Aptamer against midkine and use thereof (2011-12-20),

RIBOMIC is a bio-pharmaceutical company focused on developing and commercializing aptamer therapeutics. With a unique platform combining RNA-based drug discovery and development technologies, RIBOMIC aims to provide innovative solutions for unmet medical needs. The company's aptamer pipeline includes targeted therapies for various diseases, including cancer, viral infections, and immune disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

13 Patents

#1,452 in Tokyo

#3,660 in Japan

#43,713 in the World

Ribomic Inc.

Forward Citations = 32

19 inventors:

Yoshikazu Nakamura (10 out of 14 patents)

Shin Miyakawa (6 out of 7 patents)

Ling Jin (5 out of 6 patents)

4. Masatoshi Fujiwara (5 out of 32 patents)

5. Takashi Matsui (3 out of 109 patents)

Please report any incorrect information to support@idiyas.com

Loading…